Previous 10 | Next 10 |
-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamou...
WOODCLIFF LAKE, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”). Eagle had asserted its Orange...
-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pi...
-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products ...
-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as the beginning of 2023 -- -- CAL02 is being developed as an adjunct to the clinical...
WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certai...
Eagle Pharmaceuticals, Inc. (EGRX) Q3 2022 Earnings Conference Call November 7, 2022 08:30 ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - President & Chief Executive Officer Brian Cahill - Chief Financial Officer Conference Cal...
Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q3 Non-GAAP EPS of $1.12 beats by $0.21 . Revenue of $65.9M (+65.4% Y/Y) beats by $3.82M . Q3 2022 RYANODEX ® net product sales were $7.6 million, compared to $4.5 million in the third quarter of 20...
Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share 1 Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021 Nine-month 2022 net income was $2.41 per basic an...
Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is $0.91 (+62.5% Y/Y) and the consensus Revenue Estimate is $62.08M (+55.8% Y/Y). Over the last 2 years, EGRX h...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...